ACC

Alnylam Presents Positive Results from the KARDIA-2 Phase 2 Study of Zilebesiran Added to Standard of Care Antihypertensives in Patients with Inadequately Controlled Hypertension

Retrieved on: 
Sunday, April 7, 2024
Research, FDA, Clinical Trials, Cardiology, Biotechnology, Managed Care, Health, Pharmaceutical, Science, Blood pressure, Medication, Indapamide, Risk, Patient, Month, SBP, ABPM, American College, Olmesartan, Injection, Safety, RNA interference, Therapy, AGT, ACC, Amlodipine, Cardiomyopathy, Hypertension, Pharmaceutical industry

Zilebesiran is an investigational RNAi therapeutic targeting liver-expressed angiotensinogen (AGT) in development for the treatment of hypertension with the potential for biannual dosing.

Key Points: 
  • Zilebesiran is an investigational RNAi therapeutic targeting liver-expressed angiotensinogen (AGT) in development for the treatment of hypertension with the potential for biannual dosing.
  • The results were presented today as a late-breaking clinical trial at the 2024 American College of Cardiology (ACC) Annual Scientific Session.
  • The Company previously announced positive topline results from the KARDIA-2 study in March 2024.
  • “Although many effective oral treatments are available, a large proportion of patients with hypertension are not managed to guideline-recommended targets.

Cathie Biga is New American College of Cardiology President

Retrieved on: 
Monday, April 8, 2024
College, FACC, Culture, Practice management, NCDR, Science, Trustee, Knowledge, History, Registry, Health policy, MSN, American College, MPH, Multimedia, ACC, Health, MSCE, Nursing

ATLANTA, April 8, 2024 /PRNewswire/ -- Cathie Biga, MSN, FACC, today became president of the American College of Cardiology and made history as the organization's first non-physician president. She will serve a one-year term representing over 56,000 cardiovascular care team members around the world and leading the cardiovascular organization in its mission to transform cardiovascular care and improve heart health for all.

Key Points: 
  • ATLANTA, April 8, 2024 /PRNewswire/ -- Cathie Biga, MSN, FACC, today became president of the American College of Cardiology and made history as the organization's first non-physician president.
  • "The concept of 'standing on the shoulders of giants' is often referenced when talking about leadership changes and transformation over time.
  • She's been a member of the ACC Board of Trustees for six years, most recently serving as vice president.
  • The American College of Cardiology (ACC) is the global leader in transforming cardiovascular care and improving heart health for all.

ALTIVIA Appoints Scott Barnum as Director of Manufacturing and Dean Hale as Corporate Engineering Manager

Retrieved on: 
Monday, April 8, 2024
Health, Kerry Group, Growth, State university system, PFE, American Chemistry Council, DOW, Engineering, Buffalo Niagara, Michigan State University, Safety, Chemical engineering, Project Management Professional, Food, ACC, Corporation, Pharmacia

HOUSTON, April 8, 2024 /PRNewswire/ -- ALTIVIA today announced that it has named Scott Barnum as Director of Manufacturing and Dean Hale as Corporate Engineering Manager.

Key Points: 
  • HOUSTON, April 8, 2024 /PRNewswire/ -- ALTIVIA today announced that it has named Scott Barnum as Director of Manufacturing and Dean Hale as Corporate Engineering Manager.
  • Mr. Barnum will oversee the process management, quality, and operations of ALTIVIA's Specialty and Oxide Chemicals' units.
  • Mr. Hale will lead the development and management of ALTIVIA's Corporate Engineering Department.
  • "We look forward to welcoming both Scott and Dean as ALTIVIA furthers its investment in growth, sustainability, and world-class operating performance," said Michael Jusbasche, ALTIVIA's Chief Executive Officer.

LEADERSHIP EXCELLENCE PERSONIFIED: VICE ADMIRAL COLIN J. KILRAIN JOINS ACTIVE CRISIS CONSULTING AS MANAGING DIRECTOR AND ADVISOR TO THE BOARD

Retrieved on: 
Monday, April 8, 2024
Chief of staff, Government, Assistant, Associate, Knowledge, Special Operations Command Pacific, Defence Intelligence Agency (India), Joint Chiefs of Staff, United States Navy, McKinney, Texas, Innovation system, Central Intelligence Agency, Multimedia, ACC, Commander

DALLAS, April 8, 2024 /PRNewswire/ -- Active Crisis Consulting ("ACC") is honored to have Vice Admiral Colin James Kilrain join the company as its newest Managing Director and Board Advisor.

Key Points: 
  • DALLAS, April 8, 2024 /PRNewswire/ -- Active Crisis Consulting ("ACC") is honored to have Vice Admiral Colin James Kilrain join the company as its newest Managing Director and Board Advisor.
  • Vice Admiral Kilrain brings an incredible depth of knowledge and experience in national security and global affairs to the leadership team at ACC based on his U.S.
  • Vice Admiral Kilrain served as Assistant to the Chairman of the Joint Chiefs of Staff from 2021-2023, and as Associate Director for Military Affairs for the Central Intelligence Agency from 2019-2021.
  • Jared Febbroriello, Managing Director of Active Crisis Consulting commented:
    "We're pleased to welcome Vice Admiral Kilrain as our newest Managing Director and Board Advisor.

LEADERSHIP EXCELLENCE PERSONIFIED: VICE ADMIRAL COLIN J. KILRAIN JOINS ACTIVE CRISIS CONSULTING AS MANAGING DIRECTOR AND ADVISOR TO THE BOARD

Retrieved on: 
Monday, April 8, 2024
Chief of staff, Government, Assistant, Associate, Knowledge, Special Operations Command Pacific, Defence Intelligence Agency (India), Joint Chiefs of Staff, United States Navy, McKinney, Texas, Innovation system, Central Intelligence Agency, ACC, Commander

DALLAS, April 8, 2024 /PRNewswire/ -- Active Crisis Consulting ("ACC") is honored to have Vice Admiral Colin James Kilrain join the company as its newest Managing Director and Board Advisor.

Key Points: 
  • DALLAS, April 8, 2024 /PRNewswire/ -- Active Crisis Consulting ("ACC") is honored to have Vice Admiral Colin James Kilrain join the company as its newest Managing Director and Board Advisor.
  • Vice Admiral Kilrain brings an incredible depth of knowledge and experience in national security and global affairs to the leadership team at ACC based on his U.S.
  • Vice Admiral Kilrain served as Assistant to the Chairman of the Joint Chiefs of Staff from 2021-2023, and as Associate Director for Military Affairs for the Central Intelligence Agency from 2019-2021.
  • Jared Febbroriello, Managing Director of Active Crisis Consulting commented:
    "We're pleased to welcome Vice Admiral Kilrain as our newest Managing Director and Board Advisor.

New Health Economic Analysis Presented at ACC Highlights the Acarix CADScor System's Cost-Effectiveness

Retrieved on: 
Monday, April 8, 2024
Faculty, Chest pain, Coronary artery disease, Massachusetts General Hospital, Health, Incidence, Risk, Patient, Anxiety, MD, Master of Science, Emergency department, American College, ED, Physician, ACC, CAD, Medical device

"This not only leads to increased healthcare costs but also results in the improper utilization of resources.

Key Points: 
  • "This not only leads to increased healthcare costs but also results in the improper utilization of resources.
  • Additionally, the incidence of missed cardiac events with the CADScor System was remarkably low, indicating that the anticipated economic benefit did not compromise clinical outcomes.
  • "This study reaffirms the comprehensive value proposition of the CADScor System for patients, physicians, and payors alike.
  • Physicians can easily and quickly determine the next steps, facilitating cost efficiencies for healthcare systems and payors by reducing unnecessary testing."

American College of Cardiology Presentation Highlights Promising Results Showing Potential to Reduce Coronary Inflammation with Abcentra's Orticumab

Retrieved on: 
Monday, April 8, 2024
Cardiovascular disease, Chest pain, Psoriasis, Coronary artery disease, Risk, Inflammation, Patient, Cardiovascular Research, Death, Plaque, Artery, American College, CCTA, Apolipoprotein, Heart, ACC, FAI, Pharmaceutical industry

ATLANTA, April 8, 2024 /PRNewswire/ -- Abcentra LLC, a clinical-stage biopharmaceutical company specializing in coronary artery disease, presented the latest results from a Phase 2a pilot, placebo-controlled, randomized clinical trial of Orticumab, a new drug with a novel mechanism of action to combat coronary inflammation, at the American College of Cardiology (ACC) Annual Scientific Sessions in Atlanta. The trial revealed that treatment with Orticumab during a 15-week period significantly reduced coronary inflammation in patients with psoriasis, who have a higher risk of adverse cardiac events, associated with elevated coronary artery inflammation.

Key Points: 
  • The trial revealed that treatment with Orticumab during a 15-week period significantly reduced coronary inflammation in patients with psoriasis, who have a higher risk of adverse cardiac events, associated with elevated coronary artery inflammation.
  • Orticumab is a monoclonal antibody against oxidized low-density lipoprotein (oxLDL), a key driver of plaque inflammation and destabilization in coronary artery disease.
  • Abcentra partnered with Caristo Diagnostics to leverage its CaRi-Heart AI technology to measure changes in patients' coronary artery inflammation as result of therapeutic intervention.
  • The results from this trial indicate that targeting oxLDL with Orticumab may reduce residual inflammatory risk and improve outcomes for patients with cardiovascular disease.

American College of Cardiology Presentation Highlights Promising Results Showing Potential to Reduce Coronary Inflammation with Abcentra's Orticumab

Retrieved on: 
Monday, April 8, 2024
Cardiovascular disease, Chest pain, Psoriasis, Coronary artery disease, Risk, Inflammation, Patient, Cardiovascular Research, Death, Plaque, Artery, American College, CCTA, Apolipoprotein, Heart, ACC, FAI, Pharmaceutical industry

ATLANTA, April 8, 2024 /PRNewswire/ -- Abcentra LLC, a clinical-stage biopharmaceutical company specializing in coronary artery disease, presented the latest results from a Phase 2a pilot, placebo-controlled, randomized clinical trial of Orticumab, a new drug with a novel mechanism of action to combat coronary inflammation, at the American College of Cardiology (ACC) Annual Scientific Sessions in Atlanta. The trial revealed that treatment with Orticumab during a 15-week period significantly reduced coronary inflammation in patients with psoriasis, who have a higher risk of adverse cardiac events, associated with elevated coronary artery inflammation.

Key Points: 
  • The trial revealed that treatment with Orticumab during a 15-week period significantly reduced coronary inflammation in patients with psoriasis, who have a higher risk of adverse cardiac events, associated with elevated coronary artery inflammation.
  • Orticumab is a monoclonal antibody against oxidized low-density lipoprotein (oxLDL), a key driver of plaque inflammation and destabilization in coronary artery disease.
  • Abcentra partnered with Caristo Diagnostics to leverage its CaRi-Heart AI technology to measure changes in patients' coronary artery inflammation as result of therapeutic intervention.
  • The results from this trial indicate that targeting oxLDL with Orticumab may reduce residual inflammatory risk and improve outcomes for patients with cardiovascular disease.

Ionis presents positive results from Phase 3 Balance study of olezarsen for familial chylomicronemia syndrome

Retrieved on: 
Sunday, April 7, 2024
TGS, AP, Ionis, Incidence, Abdominal pain, IONS, Webcast, Patient, NEJM, Fasting, American College, Ionis Pharmaceuticals, FCS, ACC, Triglyceride, Annual general meeting, Medicine, Pharmaceutical industry

CARLSBAD, Calif., April 7, 2024 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced full results from the Phase 3 Balance study of Ionis' lead independent investigational medicine, olezarsen, for the treatment of adults with familial chylomicronemia syndrome (FCS). The olezarsen 80 mg monthly dose met the primary endpoint of significantly reducing triglycerides (TGs) in patients with genetically validated FCS at six months. In addition, olezarsen demonstrated robust and sustained reductions in TGs and serum apolipoprotein C-III (apoC-III) levels. Importantly, olezarsen reduced the incidence of acute pancreatitis (AP) events over the 12-month treatment period compared to placebo. Olezarsen also demonstrated a favorable safety and tolerability profile. These results were presented in an oral presentation at the 2024 American College of Cardiology (ACC) Annual Meeting in Atlanta, Georgia and published simultaneously in The New England Journal of Medicine (NEJM). Based on these data, Ionis is pursuing regulatory approval of olezarsen as a potential breakthrough treatment for adults with FCS.

Key Points: 
  • Based on these data, Ionis is pursuing regulatory approval of olezarsen as a potential breakthrough treatment for adults with FCS.
  • In the study, patients were treated with olezarsen 80 mg (n=22), 50 mg (n=21) or placebo (n=23) once every four weeks.
  • Serious AEs occurred in 14% of patients treated with olezarsen 80 mg, 19% treated with olezarsen 50 mg, and 39% treated with placebo.
  • Ionis will host a webcast to discuss the detailed results from the Balance study on Monday, April 8 at 10:00 am ET.

Leading Cardiologists from NYU Langone Heart Present Latest Clinical Findings & Research at American College of Cardiology 73rd Annual Scientific Session

Retrieved on: 
Friday, April 5, 2024
Diagnosis, Internal medicine, Ozone, Cardiovascular disease, Eugene Braunwald, System, N95, Blood, Digital, Assistant, Memory, Risk, Diabetes, Inflammation, Patient, Biomarker, Research, Moyamoya disease, Cardiovascular Research, Splenic infarction, NYU, Ischemia, IMR, Particulates, Woman, Heart failure, American College, MPH, CFR, NYU Langone Health, EHR, American Red Cross, Bangladesh Technical Education Board, Air pollution, Data, Osteoarthritis, ACC, CCD, Work, Physician, Medical device

NEW YORK, April 5, 2024 /PRNewswire/ -- Experts from NYU Langone Heart are presenting their latest clinical findings and research discoveries during the American College of Cardiology (ACC) 2024 Annual Scientific Session & Expo, held April 6 to 8 in Atlanta.

Key Points: 
  • NEW YORK, April 5, 2024 /PRNewswire/ -- Experts from NYU Langone Heart are presenting their latest clinical findings and research discoveries during the American College of Cardiology (ACC) 2024 Annual Scientific Session & Expo, held April 6 to 8 in Atlanta.
  • "The ACC conference serves as a place for our faculty to explore, learn, and share all the latest advancements in the field.
  • They will also be available for media interviews to discuss innovative and noteworthy scientific developments emerging from the conference.
  • Her research is focused on understanding what makes heart attacks in women unique and the best methods of detection and treatment.